文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

RadTARGET试验方案:中高危前列腺癌聚焦放疗联合非可疑前列腺减量的多中心II期随机对照试验

Trial protocol: RadTARGET, a multicenter phase II randomized controlled trial evaluating focal radiotherapy boost with de-intensification of dose to non-suspicious prostate in patients with intermediate- or high-risk prostate cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-05-15

RadTARGET是一项II期随机试验,旨在比较影像引导下肿瘤聚焦放疗与标准放疗在中高危前列腺癌根治性放疗中的急性泌尿生殖或胃肠道≥2级不良事件。研究干预为对影像可见肿瘤进行剂量强化、对剩余前列腺行剂量减量,主要终点为急性GU或GI≥2级不良事件。若假说成立,将支持开展III期非劣效性随机对照试验。

要点

  • 根治性放疗剂量强化改善预后但增加晚期不良事件,前列腺内复发多位于原发肿瘤部位。
  • RadTARGET对比影像引导肿瘤聚焦放疗与标准全腺放疗的急性GU或GI≥2级不良事件。
  • 研究假设肿瘤聚焦方法在保持高效的同时显著减少放疗后不良事件。

核心结论

  • RadTARGET将比较肿瘤聚焦放疗与标准放疗根治局限性前列腺癌的疗效与安全性。
  • 若肿瘤聚焦方法被证实可显著减少不良事件且保持高效,则支持开展III期非劣效性随机对照试验。

研究设计与样本

  • 多中心II期随机对照试验,纳入计划接受根治性放疗(联合或不联合全身治疗)的中危或高危前列腺癌患者。
  • 患者随机分入标准放疗剂量组或肿瘤聚焦放疗组,参与者和研究持续时间分别为5年和8年。

主要发现

  • 主要终点为随机分组间急性泌尿生殖或胃肠道≥2级不良事件。
  • 研究干预为影像引导下肿瘤聚焦放疗,对影像可见癌症行剂量强化、对剩余前列腺行剂量减量。

关键数值与推荐

  • 主要终点比较随机臂间急性GU或GI≥2级不良事件。
  • 研究人群为计划接受根治性放疗(联合或不联合全身治疗)的中危或高危前列腺癌患者。

临床怎么用

  • 为中高危前列腺癌根治性放疗提供肿瘤聚焦剂量强化联合非可疑前列腺减量的前瞻性随机证据。
  • 若结果支持,可推动III期试验正式确立肿瘤聚焦方法相对于全腺剂量强化的肿瘤学非劣效性。

局限性

  • 原文为试验方案,未报告样本量、具体剂量数值、P值或置信区间。
  • 主要终点为急性不良事件,随访时间与长期肿瘤学结局需III期试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Definitive radiotherapy (RT) for prostate cancer (PC) with dose intensification and/or focal boosting has excellent oncologic outcomes, but many patients experience adverse events. Dose escalation to the whole prostate improves outcomes at the expense of increased late adverse events. Intraprostatic recurrence after definitive RT typically occurs at the site of the primary tumor, suggesting that dose to the site of the dominant lesion is an important predictor of future failure. The efficacy and safety of tumor-focused RT compared to that of standard RT for definitive treatment of localized PC has not been assessed. RadTARGET (RAdiation Dose TAiloRing Guided by Enhanced Targeting; NCT06990542) is a phase II randomized trial that aims to demonstrate superior safety of image-guided, tumor-focused RT compared to standard RT for acute genitourinary (GU) or gastrointestinal (GI) in the setting of definitive RT for intermediate- and high-risk PC. The study intervention is image-guided, tumor-focused RT with dose intensification of cancer visible on imaging and dose de-intensification to remaining prostate. Patients will be randomized to two arms: those who receive standard RT dose and those that receive tumor-focused RT. The study population will be patients with intermediate- or high-risk PC planning to undergo definitive RT with or without systemic therapy. The primary endpoint to compare between randomized arms is acute GU or GI grade ≥2 adverse events. Participant and study duration are 5 years and 8 years, respectively. RadTARGET will compare the efficacy and safety of tumor-focused RT to that of standard RT for definitive treatment of localized PC. We hypothesize that the tumor-focused approach will substantially reduce adverse events after prostate RT while retaining high efficacy. If this hypothesis is confirmed, we will conclude that a phase III randomized control trial is warranted to formally establish oncologic non-inferiority compared to the current standard of whole-gland dose escalation.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Dornisch AM, Domingo MR, Alexander RV, et al. Trial protocol: RadTARGET, a multicenter phase II randomized controlled trial evaluating focal radiotherapy boost with de-intensification of dose to non-suspicious prostate in patients with intermediate- or high-risk prostate cancer. Clin Transl Radiat Oncol. 2026. PMID: 42205730. doi:10.1016/j.ctro.2026.101184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。